|Videos|October 16, 2020

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Author(s)David L. Porter, MD, University of Pennsylvania, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Elizabeth Budde, MD, PhD

Episodes in this series

EP. 1 How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

EP. 1 How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

AL Amyloidosis | Image Credit: © LELISAT - stock.adobe.com

October 1st, 2026

NXC-201 Elicits High Complete Response Rate in R/R AL Amyloidosis

Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.

FDA

September 30th, 2026

Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease

The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML

Revisit Every OncLive On Air Episode From September 2026

UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma

Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer